Orexo Revenue and Competitors
Estimated Revenue & Valuation
- Orexo's estimated annual revenue is currently $28.5M per year.
- Orexo's estimated revenue per employee is $201,000
Employee Data
- Orexo has 142 Employees.
- Orexo grew their employee count by 2% last year.
Orexo Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Orexo?
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but it is also our aim to address other therapeutic areas where our competence and technologies can create value. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercialize the product Zubsolv®. Other products are commercialized through partners, including sale of Zubsolv outside the US.
keywords:N/A
N/A
Total Funding
142
Number of Employees
$28.5M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Orexo's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Specialty Sales Representative | Reveal Email/Phone |
2 | Healthcare Liason | Reveal Email/Phone |
3 | Regional Sales Manager - West | Reveal Email/Phone |
4 | Southeast Regional | Reveal Email/Phone |
5 | SVP Market Access, Government Affairs & Marketing | Reveal Email/Phone |
6 | Regional Sales Manager | Reveal Email/Phone |
7 | analytisk kemist | Reveal Email/Phone |
8 | Specialty Sales Representative/ National Field Trainer | Reveal Email/Phone |
9 | Chief Medical Officer | Reveal Email/Phone |
10 | Senior Consultant | Reveal Email/Phone |
Orexo News
UPPSALA, Sweden, April 21, 2022 /PRNewswire/ --. Election of the board of directors and auditor. The annual general meeting in Orexo AB...
Why Does Debt Bring Risk? · What Is Orexo's Net Debt? · How Healthy Is Orexo's Balance Sheet? · So How Risky Is Orexo? · Discounted cash flow...
Orexo provides information about its new proprietary drug delivery platform – amorphOX[TM] Fri, Nov 26, 2021 08:00 CET amorphOXTM is a novel and inventive drug delivery platform that can be used to develop highly differentiated products with various active ingredients and administration routes ...
Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124 Tue, Nov 16, 2021 08:00 CET The pivotal trial OX124-002 meets the primary endpoints in the 4-period crossover, comparative bioavailability study in healthy volunteers OX124 showed a significa ...
Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124 Tue, Nov 16, 2021 08:00 CET The pivotal trial OX124-002 meets the primary endpoints in the 4-period crossover, comparative bioavailability study in healthy volunteers OX124 showed a significa ...
Other Companies in Morristown
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16M | 145 | 7% | N/A |
#2 | $40.3M | 146 | 16% | N/A |
#3 | $3.5M | 151 | 26% | N/A |
#4 | $35.6M | 154 | 8% | N/A |
#5 | $35.2M | 156 | -4% | N/A |
Orexo Executives
| Name | Title |
|---|---|
| Joseph DeFeo | CFO |
| Nikolaj Sørensen | President and CEO |
| Henrik Juuel | EVP and Chief Financial Officer |
| Jesper Lind | Chief Operating Officer |
| Michael Sumner | Chief Medical Officer |
| Mike Sumner | Chief Medical Officer |
| Nikolaj Sorensen | CEO and President |
| Nikolaj Sørensen | President and CEO |
| Henrik Juuel | EVP and Chief Financial Officer |
| Dennis Urbaniak | Executive Vice President Digital Health |
| Rich Murphy | Senior Vice President Market Access, Government Affairs & Marketing |
| Dennis Urbaniak | Executive Vice President Digital Therapeutics |
| Mike Myers | Senior Vice President - Commercial Head |
| Nikolaj Sorensen | CEO and President |
| Robert Rönn | SVP and Head of R&D |
| Cecilia Coupland | Vice President, Head of Operations |
| Petter Wereen | Vice President Procurement and Business Development |